Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1789192 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $1.48Day −4.52%Mkt cap $2MOff 52W high −93.8%Vol (1Y) 295.1%
Daily closing price, split-adjusted to the current basis; 0.4y shown of 96 bars on file. Sampled to 96 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest2.2% of sh out |
| Days to cover1.0d |
| 13F net flow (QoQ)+1.15% |
| Top-10 13F concentration100.0% |
| Next report (est.)2026-08-13 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$9.4M |
| ROE−38.6% |
| ROIC−42.5% |
| Debt / equity0.09× |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
No return windows available for NXTS.
| Ann. volatility (1Y)295.1% |
| Ann. volatility (3Y)295.1% |
| Sharpe (1Y)−0.41 |
| Sharpe (3Y)−0.41 |
| Max drawdown (1Y)−88.6% |
| Max drawdown (3Y)−88.6% |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 49,840 | $31,130 | 3.87% | new |
| XTX Topco Ltd | 21,764 | $14,364 | 1.69% | new |
| Yorkville Advisors Global, LP | 16,409 | $10,830 | 1.27% | new |
| UBS Group AG | 13,105 | $8,649 | 1.02% | +614.2% |
| VANGUARD FIDUCIARY TRUST CO | 6,987 | $4,611 | 0.54% | new |
| Tower Research Capital LLC (TRC) | 4,502 | $2,971 | 0.35% | +363.6% |
| SBI Securities Co., Ltd. | 58 | $38 | 0.00% | +1.8% |
| MORGAN STANLEY | 5 | $3 | 0.00% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | −$10.74 | — | — | — |
| 2025-09-30 | 2025-11-13 | $0.97 | — | $2,000 | −77.8% |
| 2025-06-30 | 2025-08-14 | −$0.18 | — | — | — |
| 2025-03-31 | 2025-05-15 | −$85.25 | — | $66,000 | +50.6% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-13 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
